Veeva Launches AI-Powered Study Builder Agent to Accelerate Clinical Trial Configuration
Event summary
- Veeva Systems introduced Veeva Study Builder Agent, an AI solution that configures clinical studies directly from study protocols.
- The agent leverages existing standards and CDISC USDM to automate EDC and DQS builds, reducing configuration time to as little as one day.
- Early adopter availability is planned for December 2026, with no additional licensing required.
- The solution will be showcased at the Veeva R&D and Quality Summit in Boston on October 20-21, 2026.
The big picture
Veeva's new AI solution underscores the growing trend of automation in clinical trials, aiming to reduce manual configuration time and enhance consistency. By leveraging existing standards and CDISC USDM, Veeva is positioning itself as a leader in simplifying and standardizing clinical trial processes. The move comes as life sciences companies increasingly seek to accelerate drug development timelines and reduce operational inefficiencies.
What we're watching
- Adoption Pace
- How quickly life sciences companies will integrate the AI-powered Study Builder Agent into their clinical trial workflows.
- Competitive Response
- Whether competitors in the clinical trial software space will accelerate their own AI-driven automation efforts.
- Regulatory Compliance
- The extent to which the agent's audit-ready design will streamline regulatory approval processes.
Related topics